Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma

Japanese Journal of Cancer Research : Gann
A SuzukiT Tominaga

Abstract

Several oncoproteins or tumor suppressor gene products have been indicated to be of value as predictors of the de novo resistance to cytotoxic agents. In this study, we have investigated the role of MDM2 (murine double minutes) overexpression in doxorubicin resistance of breast cancer. Immunocytochemical analysis demonstrated that MDM2-positive tumors, even with p53-negative phenotype, were significantly more resistant to doxorubicin treatment compared to MDM2-negative tumors. An in vitro experimental model using stable mdm2-transfected MCF-7 cells carrying wild-type p53 confirmed that the cells become approximately 3-fold more resistant to doxorubicin as a result of MDM2 overexpression, and the wild-type p53 function, such as the induction of p21Waf1 following DNA damage, was significantly suppressed. MDM2 overexpression is suggested to be a novel marker for predicting lack of response to doxorubicin treatment in breast cancer patients.

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A GustersonR Reed
May 1, 1987·Somatic Cell and Molecular Genetics·L Cahilly-SnyderD L George
Oct 1, 1993·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·S M Picksley, D P Lane
Jun 1, 1995·Nature Genetics·X W WangB G Taffe
Jul 1, 1993·Molecular and Cellular Biology·J ChenA J Levine
Jan 1, 1995·The Journal of Pathology·A MarchettiM Barbareschi
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B QuesnelJ P Peyrat
Nov 4, 1994·Science·S W LoweT Jacks
Sep 7, 1994·Journal of the National Cancer Institute·P LianesC Cordon-Cardo
Sep 7, 1994·Journal of the National Cancer Institute·T HabuchiO Yoshida
Nov 19, 1993·Cell·W S el-DeiryB Vogelstein
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·G BakalkinK G Wiman
Jul 1, 1993·Genes & Development·X WuA J Levine
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K Roemer, T Friedmann

❮ Previous
Next ❯

Citations

Aug 24, 2000·Molecular Medicine Today·E H ChangK B Bouker
Feb 17, 2001·Biochemical and Biophysical Research Communications·S SajiS Hayashi
Sep 25, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Laura SmithLynn Cawkwell
Feb 1, 2006·Expert Opinion on Therapeutic Patents·Jinxia DengNouri Neamati
Mar 18, 2004·British Journal of Cancer·H-J TangJ Lin
Aug 24, 2019·Cancer Cell International·Helei HouXiaochun Zhang
Nov 10, 2020·Archives of Pharmacal Research·Jinyoung ParkEun Joo Song
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhuo ZhangRuiwen Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.